Protected by copyright, including for uses related to text and data mi

BMJ Open Economic evaluation of the hospitalist care model in an acute medical unit: a benefit-cost analysis

Hyun Jeong Kim (1), 1,2 Jinhyun Kim (1), 1 Jung Hun Ohn (1), 3,4 Nak-Hyun Kim (1), 3,4

To cite: Kim HJ, Kim J, Ohn JH, et al. Economic evaluation of the hospitalist care model in an acute medical unit: a benefit-cost analysis. BMJ Open 2024;14:e081594. doi:10.1136/ bmjopen-2023-081594

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2023-081594).

Received 01 November 2023 Accepted 29 June 2024



@ Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by

¹College of Nursing, Seoul National University, Seoul, Republic of Korea ²Department of Nursing, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea

³Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

⁴Hospital Medicine Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea

Correspondence to

Dr Jinhyun Kim; jinhyun@snu.ac.kr

ABSTRACT

Objective This study aimed to assess the economic efficiency of the acute medical unit (AMU) hospitalist care model, utilising patient outcomes (length of hospital stay, emergency department (ED)-length of hospital stay, inhospital mortality) from a previous investigation.

Design A retrospective cohort study was conducted using benefit-cost analysis from a societal perspective. Data relating to clinical factors, outcomes and medical costs were obtained from the electronic medical record database at our institution. Literature-based costing was applied to determine direct non-medical costs and indirect costs that could not be obtained directly.

Setting A tertiary care hospital in the Republic of Korea. **Participants** We evaluated 6391 medical inpatients admitted through the ED from 1 June 2016 to 31 May

Interventions The study compared multiple types of costs and benefits among inpatients from the ED between a non-hospitalist group and an AMU hospitalist group.

This investigation found a significant reduction in medical costs and total costs in the AMU hospitalist group compared to the non-hospitalist group (30% reduction, 95% CI: 27.6–32.1%, *P*=0.000; 29.3% reduction, 95% Cl: 27.0–31.5%, *P*=0.000; respectively). Furthermore, significant reductions in direct and indirect costs were found in the AMU hospitalist group compared to the nonhospitalist group (28.6% reduction, 95% CI: 26.6-30.5%, P=0.000; 23.3% reduction, 95% CI: 20.9-25.5%, P=0.000; respectively). The net-benefit and benefit-cost ratio (BCR) of the AMU hospitalist care group were US \$6846 and 1.33 per patient admission, respectively. **Conclusions** The AMU hospitalist care model was associated with remarkable reductions in multiple costs. The results of the sensitivity analysis indicated that the net-benefit estimates of AMU hospitalist care were similar to the baseline estimates. Thus, the overall net-benefit of AMU hospitalist care was found to be largely positive.

INTRODUCTION

In South Korea, a pilot hospitalist care system was implemented from 2016 to address reduced numbers of medical personnel and improve the quality of inpatient care. The pilot project was integrated within the general hospital care system after 5 years, and the number of hospitalists in Korea has

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ In this study, extensive cost analysis was conducted from a societal perspective.
- ⇒ The study encompassed all medical inpatients who were admitted from the emergency department to medical wards throughout the specified time frame from 1 June 2016 to 31 May 2017. Having such broad inclusion criteria is likely to have enhanced the validity of the findings.
- ⇒ Making generalisations regarding this retrospective study is challenging because of its singular institution of origin.
- ⇒ Expenditures apart from medical costs were not obtained directly but were calculated after consulting relevant sources; therefore, a degree of uncertainty may remain in the cost estimates.
- ⇒ This study could not quantify the potential benefits associated with a reduction in admissions to the intensive care unit. Therefore, the benefits determined in this study may have been undervalued.

increased to approximately 250.2 Under the hospitalist care model, a dedicated specialist takes comprehensive responsibility directly and provides managed care to patients during admission, whereas under the non-hospitalist care model, a resident provides care to patients during admission under the supervision of a specialist.

Since the implementation of the hospitalist care system in Korea, research on patient outcomes has been conducted³⁻⁹ in terms of in-hospital mortality (IHM), intensive care unit (ICU) admission, emergency department-length of stay (ED-LOS) and total length of hospital stay (LOS). Although there have been many studies on the effectiveness of the hospitalist system, few studies have been undertaken on costs or involving economic evaluations. While some studies have reported on the medical costs of hospitalist care in South Korea,^{7 10} no economic evaluations from a societal perspective have been reported concerning hospitalist care in South Korea. Therefore, evaluating the economic efficiency of hospitalist care is



In this study, a societal-perspective economic evaluation was conducted to estimate the overall costs and benefits of the acute medical unit (AMU) hospitalist care model implemented at our institution, based on patient outcomes. We aimed to provide new evidence on the economic efficiency of the AMU hospitalist care model.

METHODS

Study participants and AMU setting

We evaluated 6391 medical inpatients admitted through the emergency department (ED) of our institution from 1 June 2016 to 31 May 2017, who were assigned to AMU hospitalist care and non-hospitalist care groups (2426 and 3965 patients, respectively). The AMU patients were evaluated and treated by four hospitalists with an average of 10 years of clinical experience in infectious diseases, pulmonology and critical care, nephrology and endocrinology. Seven days per week, two AMU hospitalists were responsible for the care of the AMU patients admitted during the day. In addition, non-hospitalist inpatient care was provided by subspecialists and residents in a specialty medical ward, where residents were primarily responsible for inpatient care under the supervision of an attending physician. While hospitalist care in the AMU focused on general acute care, non-hospitalist care in the specialty medical ward emphasised long-term and specialised treatment.9

Study design

This retrospective cohort study compared and analysed the cost-saving benefits, calculated based on costs and patient outcomes, between AMU hospitalist care and non-hospitalist care groups for patients admitted through the ED at a tertiary hospital.

We conducted a benefit-cost analysis and divided costs into medical costs, non-medical costs and time costs in terms of productivity loss. 11 This investigation was conducted in accordance with Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022).¹² A flow diagram of the study population and benefit-cost factors is presented in online supplemental 1.

Outcomes and clinical variables

Outcomes and clinical variables were obtained from the electronic medical records (EMRs) at our institution. Among the outcome variables, IHM, LOS and ED-LOS were used to calculate costs and benefits as well as the time cost of productivity loss. Productivity loss is the time

cost incurred as a result of mortality or disease-related restrictions on productive activities due to admission.¹³

We analysed the following clinical variables of the participants: age, sex, prior hospitalisation history, cardiopulmonary resuscitation (CPR) incidence, cause of ICU admission, referral to a specialty, consultations, surgical intervention (cases performed during the hospitalisation, not before), major diagnosis (based on the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM))), Korean Triage and Acuity Scale (KTAS), Ageadjusted Charlson Comorbidity Index (ACCI) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. The ACCI score is derived from the sum of 1, 2, $\boldsymbol{\xi}$ 3 and 6 weighted values for 17 disease groups, ranging 8 from 0 to 29; higher scores indicate higher severity. 14 The KTAS, which is currently applied in emergency medical centres in Korea, is a national standardised classification tool for evaluating illness severity. 15 We used the APACHE II score to compare the disease severity among ICU admissions; this score (range: 0-71) has been found to closely correlate with the risk of hospital death. ¹⁶ Baseline characteristics of the study population are presented in table 1.9

Cost measures

Micro-costing and gross-costing were used for cost calculation in this study. Micro-costing was applied to directly calculate the medical costs during the total hospital stay. 1 Gross-costing was used to calculate all costs other than medical costs (online supplemental 2). The costs were classified into direct costs and indirect costs, 13 with all classified into direct costs and indirect costs, with all unit costs converted to United States (US) dollars as of 2023.

Direct costs

Direct costs comprised medical costs (micro-costing), family caregiver transportation fares, paid care costs and doctor labour costs in hospitalisation (gross-costing). Healthcare in South Korea is a single-payer system organised through the National Health Insurance Service (NHIS). Nearly all citizens receive universal medical care through this system. 18 The governance of National Health Insurance in South Korea is presented in online supplemental 3. The health security system in Korea has two components: mandatory social health insurance and medical aid. In Korea, fee-for-service has been the standard payment model for outpatient care and the majority of inpatient care, leading to an increase in the volume & of services that healthcare professionals can provide.¹⁹ Medical costs in this study comprised reimbursements issued to medical providers by the NHIS and co-payments paid to medical providers by patients.

Medical cost data were obtained from hospital administrative information in the EMRs at our institution regarding consultation fee, admission fee (mainly hospital room expense, including for isolation, intensive care and general hospital room), medication fee (medication/



Baseline characteristics	Hospitalists (n=2426)	Non-hospitalists (n=3965)	P value	
Sex				
Male	1387 (57.2)	2188 (55.2)	0.120	
Female	1039 (42.8)	1777 (44.8)		
Age (years)	63.24±16.20	67.38±16.52	<0.001	
<50	488 (20.1)	610 (15.4)	<0.001	
50–59	401 (16.5)	499 (12.6)		
60–69	542 (22.3)	733 (18.5)		
70–79	632 (26.1)	1131 (28.5)		
≥80	363 (15.0)	992 (25.0)		
Prior hospitalisation	2101 (86.6)	3373 (85.1)	0.090	
Number of prior hospitalisations	3.16±4.07	3.24±4.20	0.480	
Korean Triage and Acuity Scale				
1 (Resuscitation)	12 (0.5)	69 (1.7)	<0.001	
2 (Emergency)	324 (13.4)	941 (23.7)		
3 (Urgent)	1699 (70.0)	2511 (63.3)		
4 (Less urgent)	367 (15.1)	403 (10.2)		
5 (Non-urgent)	24 (1.0)	41 (1.0)		
Major disease	,	. ,		
Malignant neoplasms	845 (34.8)	890 (22.4)	<0.001	
Diseases of the circulatory system		552 (13.9)		
Diseases of the respiratory system		875 (22.1)		
Diseases of the digestive system	441 (18.2)	424 (10.7)		
Diseases of the genitourinary system	202 (8.3)	375 (9.5)		
Symptoms, signs, and abnormal clinical and laboratory findings	162 (6.7)	167 (4.2)		
Certain infectious and parasitic diseases	86 (3.5)	204 (5.1)		
Endocrine, nutritional and metabolic diseases	95 (3.9)	158 (4.0)		
Diseases of the blood and blood- forming organs and certain disorders involving the immune mechanism	130 (5.4)	47 (1.2)		
Diseases of the musculoskeletal system and connective tissue	58 (2.4)	89 (2.2)		
Others	93 (3.8)	184 (4.6)		
Age-adjusted Charlson Comorbidity index	3.82±2.63	3.77±2.19		
Median (IQR)	4(2-5)	4(2-5)	0.055	
≤2	729 (30.0)	1018 (25.7)	0.001	
3	436 (18.0)	733 (18.5)		
4	502 (20.7)	943 (23.8)		
≥5	759 (31.3)	1271 (32.1)		
Surgical intervention	282 (11.6)	560 (14.1)	0.004	
CPR incidence	15 (0.6)	35 (0.9)	0.244	
Consultation	1830 (75.4)	2946 (74.3)	0.312	
Number of consultations	3.50±6.18	3.99±7.02	0.004	
Referral to a specialty	1613 (66.5)	450 (11.3)	<0.001	

Continued

Baseline characteristics	Hospitalists (n=2426)	Non-hospitalists (n=3965)	P value
Haematology and Oncology	658 (40.8)	114 (25.3)	<0.001
Gastroenterology	360 (22.3)	20 (4.4)	
Respiratory	174 (10.8)	53 (11.8)	
Nephrology	96 (6.0)	11 (2.4)	
Infection	96 (6.0)	8 (1.8)	
Geriatrics	80 (5.0)	9 (2.0)	
Others	149 (9.2)	235 (52.2)	
Outcomes			
In-hospital mortality	117 (4.8)	361 (9.1)	<0.001
ICU admission	95 (3.9)	343 (8.7)	<0.001
Cause of ICU admission (n=438)			
Close monitoring after procedure or surgical intervention	55 (57.9)	223 (65.0)	0.077
Respiratory failure or insufficiency	23 (24.2)	78 (22.7)	
Septic shock	7 (7.4)	17 (5.0)	
Cardiovascular failure or insufficiency	7 (7.4)	12 (3.5)	
Metabolic/renal failure	0 (0.0)	8 (2.3)	
GI bleeding	3 (3.2)	2 (0.6)	
Neurogenic dysfunction	0 (0.0)	3 (0.9)	
APACHE II score at ICU admission n=438)	25.20±10.62	21.26±12.03	0.004
ength of hospital stay (days)	10.56±11.68	11.40±12.36	
Median (IQR)	7 (4–10 47 48)	8 (5–11 47 48)	0.007
ED-LOS (hours)	11.24±8.49	13.74±10.11	
Median (IQR)	8.4 [6.1–12.7)	10.2 [6.7–19.0)	<0.001
Readmission within 10 days	117 (4.8)	177 (4.5)	0.507
Readmission within 30 days	277 (11.4)	416 (10.5)	0.248

Data are presented as the mean±SD, number (%), or median (IQR), as indicated. 'Surgical intervention' implies the patient underwent surgery during the hospital stay, not before

. APACHE, Acute Physiology and Chronic Health Evaluation; CPR, cardiopulmonary resuscitation; ED-LOS, emergency department-length of stay; GI bleeding, Gastrointestinal bleeding; ICU, intensive care unit; IQR, interquartile range.

injection/anaesthesia/whole blood and blood product), treatment and surgery fee, medical examination fee (inspection/medical imaging/CT/MRI/positron emission tomography/ultrasonography), therapeutic materials and other factors (prosthetics, orthodontics/rehabilitation and physiotherapy/ psychotherapy).

The family caregiver transportation fare in relation to hospitalisation was estimated by multiplying referenced costs (2017 Korea Health Panel Study²⁰ and the 2017 Consumer Price Index²¹) by individual patient's LOS. The term 'family caregiver transportation costs' referred to the mean expenses for round-trip transportation for each visit of a family caregiver to a medical facility during the patient's hospitalisation.²⁰ The paid care cost was calculated by multiplying the referenced average costs²² by individual patient's LOS. During the day, hospitalists administer care to patients in the hospitalist

Protected by copyright, including for uses related to text and data mining, Al training, and care group while residents provide care under the direction of a subspecialist. During the night, residents care for patients in both groups. The daytime doctor labour costs were estimated and analysed separately for residents, subspecialists and hospitalists (online supplemental files 2 and 4). Resident doctor labour costs per patient were estimated using the following variables: the average after-tax salary (2017 resident training environment evaluation survey results²³), four major social insurance scheme classifications (national pension, health insurance, employment insurance and workers' compensation insurance 24) and tax (income tax and resident tax²⁵), the number of inpatients per physician²⁶ and the total patient days (the total number of days for all inpatients) in the non-hospitalist care group. Subspecialist labour costs were calculated using a referenced average labour cost,²⁷ the number of inpatients



per physician²⁸ and the total patient days in the nonhospitalist care group.

The AMU hospitalist labour costs per patient were calculated using a referenced average labour cost, 30 the number of AMU hospitalists and AMU-LOS in the hospitalist care group. In addition, doctor labour costs for night shifts were estimated by reflecting the number of patients under the charge of residents, ³¹ residents' average wage and total patient days in the non-hospitalist care group.

Indirect costs

Indirect costs (time costs) were calculated by applying the gross-costing method. Patient productivity loss during hospitalisation (time costs) was calculated by multiplying the average daily wage by gender and age,³² by individual LOS and by the labour force participation rate. 33 Family caregiver productivity loss was calculated by multiplying the average daily wage of all workers³² by individual LOS. Patient productivity loss due to ED-LOS was calculated by multiplying the average hourly wage by gender and age,³ by individual ED-LOS and by the labour force participation rate.³³ Patient productivity loss due to death in hospitalisation was calculated by multiplying the average annual wage by gender and age, 32 by the labour force participation rate 33 and by individual life years gained in relation to death.³⁴ Individual life years gained were estimated by subtracting life expectancy reduced by major diseases from life expectancy by gender and age, in reference to life tables available from the Korean Statistical Information Service (KOSIS, 2017).³⁴

Benefit measure

In this study, the human capital approach was used as a method of evaluating the value of 'health' or 'life' in monetary units.¹⁷ Benefits, in the form of cost savings, were then estimated based on direct and indirect costs.

Economic evaluation: benefit-cost analysis

In benefit-cost analysis, the BCR and net-benefit are used as indicators for decision indices. Net-benefit refers to the benefit minus the cost, with a larger net-benefit indicating a more favourable benefit-cost situation. ¹⁷ Therefore, we used BCR and net-benefit as indicators in terms of decision indices.

Sensitivity analysis

This study is a retrospective study of costs incurred. As the study period comprised only 1 year, a discount rate was not applied to the costs and a sensitivity analysis was performed on uncertain variables.³⁵ The results of the sensitivity analysis are presented in a tornado diagram (figure 1).

First, a sensitivity analysis was conducted on LOS and ED-LOS, which showed a skewed distribution. We analysed the 1%-trimmed mean by calculating the average of the remaining values while excluding some (1%) from the extremes of the data.

Second, a sensitivity analysis was conducted on paid care costs among the direct non-medical costs that were

considered to have high uncertainty. Assuming that no caregiver was hired, the baseline paid care costs were set at \$53,²² and the maximum daily paid care costs for hospitalised patients were set at \$122.2

Third, a sensitivity analysis was conducted on doctor labour costs among the direct non-medical costs that were considered to have high uncertainty, with both one-way and two-way sensitivity analyses conducted. Resident labour costs were set at \$44180 as a baseline, with a minimum value of \$37350 and a maximum value of \$52,669.²³ Hospitalist and specialist labour costs were set at \$115452 as a baseline,^{27 30} with a minimum value of \$76458 and a maximum value of \$152917.

Statistical analysis

Categorical variables are reported as percentages and continuous variables as mean±SD. Groups were compared by conducting Pearson's χ^2 tests or t-tests, as appropriate. ACCI, LOS and ED-LOS were expressed as the median and IQR. For these variables, groups were compared by conducting the Mann-Whitney U test, owing to their skewed distributions. We performed subgroup analyses of costs and benefits according to age, the severity of the patient's condition (based on the KTAS score), the degree of comorbidity (based on the ACCI score) and the major disease category (based on the ICD-10). Natural log-transformed multivariable regression analysis was conducted in relation to the costs. As the unit cost was large, using a natural logarithm can increase normality and enable accurate values to be obtained during analysis as well as reduce skewness and kurtosis of the data. Regression analysis for the costs was used to adjust for the following factors: age, sex, prior hospitalisation, referral to specialty, consultation, CPR, KTAS score, ACCI score, **3** surgical intervention, major disease, ICU admission, IHM, LOS and ED-LOS. Using the estimates from the 9 regression models, we presented differences between AMU hospitalised and non-hospitalised groups in terms of medical, direct, indirect, and total costs.


Patient and public involvement

This was a non-interventional study conducted retrospectively. Consequently, no patients participated directly in the study's conception, formulation of research objectives and queries, or execution. In addition, patients were not involved in the interpretation of results or production of the manuscript. It is not currently in our intentions to disseminate the findings to the study participants.

RESULTS

Costs

All costs are presented as costs per patient admission in this study. The estimated costs ³⁶ between the hospitalist group and the non-hospitalist group are presented in table 2. The total costs were significantly lower in the hospitalist group than in the non-hospitalist group, with a difference of more than \$6000 (20570±91024 vs






Figure 1 One-way sensitivity analysis for the length of hospital stay, emergency department-length of stay and paid care costs. Supplementary Materials: online supplemental 1: Flow diagram of the study population and benefit–cost factors; online supplemental 2: Type of costs, cost estimation formula and data source; online supplemental 3: Governance of National Health Insurance in South Korea; online supplemental 4: Doctor labour cost estimation by patient flow and timeline; online supplemental 5: Cost analysis for urgent and non-urgent cases treated by hospitalists or non-hospitalists (N=6391); online supplemental 6: Cost analysis for patients with different comorbidity severities treated by hospitalists or non-hospitalists (N=6391); online supplemental 7: Cost analysis according to major diseases between hospitalist and non-hospitalist groups (N=6391); online supplemental 8: Cost analysis according to age between hospitalist and non-hospitalist groups (N=6391); online supplemental 9: Natural log-transformed multivariable regression analysis for medical costs and total costs (N=6391); online supplemental 10: Natural log-transformed multivariable regression analysis for direct costs and indirect costs (N=6391); online supplemental 11: One-way sensitivity analysis for resident labour costs; online supplemental 12: One-way sensitivity analysis for hospitalist labour costs; online supplemental 13: Two-way sensitivity analysis for hospitalist and specialist labour costs.

27416 \pm 102360, p=0.007). The direct medical costs were significantly lower in the hospitalist group than in the non-hospitalist group, with a difference of more than \$900 (4075 \pm 6504 vs 5050 \pm 7255, p=0.000).

Among the subcategories of medical costs, the biggest difference was found in relation to the admission fee and medical examination fee (886 ± 1661 vs 1167 ± 1697 , p=0.003; 1269 ± 1629 vs 1565 ± 1676 , p=0.000; respectively). Among the direct non-medical costs, the family caregiver transportation fare, paid care costs and doctor labour costs were significantly lower in the hospitalist group than in the non-hospitalist group (p=0.007, p=0.007 and p=0.000; respectively).

The indirect costs were significantly lower in the hospitalist group than in the non-hospitalist group, with a difference of more than \$5000 (14988±89375 vs 20719±100689, p=0.021). Among the indirect costs, family caregiver productivity loss according to LOS and patient productivity loss according to ED-LOS and IHM

were significantly lower in the hospitalist group than in the non-hospitalist group (p=0.007, p=0.000 and p=0.023, respectively). However, there were no significant differences between the two groups in terms of patient productivity loss according to LOS (560 ± 782 vs 549 ± 788 , p=0.570).

Subgroup cost differences according to KTAS scores, comorbidity severity, major disease and age

Cost analysis was performed according to subgroups of patients stratified by KTAS scores, ACCI scores, major disease and age to determine differences between the two groups (online supplemental 5–8). Compared with the non-hospitalist group, the hospitalist group's overall costs for more urgent cases were significantly reduced by more than \$8000 (p=0.002). In low-to-moderate comorbidity groups (ACCI=0–2, 3 and 4 points), there was a greater cost reduction in the hospitalist group than in the

Total costs 20570±91024 27416±102360 0.007 Direct costs 5582±8003 6697±8729 0.000 Direct medical costs 4075±6504 5050±7255 0.000 Consultation fee 251±221 269±238 0.003 Admission fee 886±1661 1167±1697 0.000 Medication fee 907±2345 889±2324 0.774 Treatment and surgery fee 266±1092 432±1720 0.000 Medical examination fee 1269±1629 1565±1676 0.000 Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Poctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Patient product	5582±8003 4075±6504	6697±8729	
Direct medical costs	4075±6504		0.000
Consultation fee 251±221 269±238 0.003 Admission fee 886±1661 1167±1697 0.000 Medication fee 907±2345 889±2324 0.774 Treatment and surgery fee 266±1092 432±1720 0.000 Medical examination fee 1269±1629 1565±1676 0.000 Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to LOS 16±75 86±90 0.000 Deata are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023) 18871±100401 0.023		5050+7255	
Admission fee 886±1661 1167±1697 0.000 Medication fee 907±2345 889±2324 0.774 Treatment and surgery fee 266±1092 432±1720 0.000 Medical examination fee 1269±1629 1565±1676 0.000 Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 76±75 86±90 0.000 Patient productivity loss according to LOS 13228±88992 18871±100401 0.023 Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023) 18871±100401 0.023	051 001	JUJU±12JJ	0.000
Medication fee 907±2345 889±2324 0.774 Treatment and surgery fee 266±1092 432±1720 0.000 Medical examination fee 1269±1629 1565±1676 0.000 Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to ED-LOS 76±75 86±90 0.000 Patient productivity loss according to LOS 13228±88992 18871±100401 0.023	251±221	269±238	0.003
Treatment and surgery fee 266±1092 432±1720 0.000 Medical examination fee 1269±1629 1565±1676 0.000 Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 76±75 86±90 0.000 Patient productivity loss according to HM 13228±88992 18871±100401 0.023	886±1661	1167±1697	0.000
Medical examination fee 1269±1629 1565±1676 0.000 Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to ED-LOS 76±75 86±90 0.000 Patient productivity loss according to HM 13228±88 992 18871±100401 0.023	907±2345	889±2324	0.774
Therapeutic materials 304±866 552±1477 0.000 Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to LOS 76±75 86±90 0.000 Patient productivity loss according to IHM 13228±88992 18871±100401 0.023	266±1092	432±1720	0.000
Others 191±596 176±467 0.249 Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to LOS 76±75 86±90 0.000 Patient productivity loss according to ED-LOS 13228±88992 18871±100401 0.023	1269±1629	1565±1676	0.000
Direct non-medical costs 1508±1688 1647±1786 0.002 Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to ED-LOS 76±75 86±90 0.000 Patient productivity loss according to IHM 13228±88992 18871±100401 0.023	304±866	552±1477	0.000
Family caregiver transportation fare in hospitalisation 198±219 213±231 0.007 Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to ED-LOS 76±75 86±90 0.000 Patient productivity loss according to IHM 13228±88992 18871±100401 0.023	191±596	176±467	0.249
Paid care cost in hospitalisation 556±614 600±650 0.007 Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to ED-LOS 66±75 86±90 0.000 Patient productivity loss according to ED-LOS 13228±88992 18871±100401 0.023 Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023)	1508±1688	1647±1786	0.002
Doctor's labour cost 754±855 834±904 0.000 Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to ED-LOS 76±75 86±90 0.000 Patient productivity loss according to IHM 13228±88992 18871±100401 0.023	198±219	213±231	0.007
Indirect costs 14988±89375 20719±100689 0.021 Patient productivity loss according to LOS 560±782 549±788 0.570 Family caregiver productivity loss according to LOS 1124±1243 1213±1316 0.007 Patient productivity loss according to ED-LOS 76±75 86±90 0.000 Patient productivity loss according to IHM 13228±88992 18871±100401 0.023	556±614	600±650	0.007
Patient productivity loss according to LOS Family caregiver productivity loss according to LOS Patient productivity loss according to LOS Patient productivity loss according to ED-LOS Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023)	754±855	834±904	0.000
to LOS Family caregiver productivity loss according to LOS Patient productivity loss according to ED-LOS Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023)	14988±89375	20719±100689	0.021
according to LOS Patient productivity loss according to ED-LOS Patient productivity loss according to ED-LOS Patient productivity loss according to IHM Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023)	560±782	549±788	0.570
to ED-LOS Patient productivity loss according 13228±88992 18871±100401 0.023 to IHM Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023)	1124±1243	1213±1316	0.007
to IHM Data are presented as mean±SD. Cost unit: USD (US\$), (\$1=1307.9 KRW, year: 2023)	76±75	86±90	0.000
	13228±88992	18871±1 00 401	0.023
ED 200, energency department length of stay, fro, hospitalist group, if livi, in hospital stay, for hospitalist group.		ortality; LOS, length of hospital stay; NHG, non	-hospitalist group.
	•	Benefit-cost analysis Net-benefit and BCR anal	ysis were conducted according
8199, p=0.016; respectively). Net-benefit and BCR analysis were conducted according	s, in all but three disease hospitalist group decreased	by clinical variables, KTA	S scores, ACCI scores, major
20 Eoo, emergency department length of sta	J: a	191±596 1508±1688 198±219 556±614 754±855 14988±89375 560±782 1124±1243 76±75 13228±88992 SD (US\$), (\$1=1307.9 KRW, year: 2023) by; HG, hospitalist group; IHM, in-hospital modules of the company of the comp	191±596 1508±1688 1647±1786 198±219 213±231 556±614 600±650 754±855 834±904 14988±89375 20719±100689 560±782 549±788 1124±1243 1213±1316 76±75 86±90 13228±88992 18871±100401 SD (US\$), (\$1=1307.9 KRW, year: 2023) by; HG, hospitalist group; IHM, in-hospital mortality; LOS, length of hospital stay; NHG, non proposition of the total group and supposition of the total

Among the major diseases, in all but three disease types, the overall cost in the hospitalist group decreased compared with the non-hospitalist group (online supplemental 7). In a subgroup analysis by age, total costs in the hospitalist group decreased in almost all age groups (p=0.248, p=0.004, p=0.000, p=0.002, p=0.001, respectively).

Natural log-transformed multivariable regression analysis of

We performed natural log-transformed multivariable regression analysis to adjust for clinical variables and outcome variables potentially associated with costs, namely, medical, direct, indirect and total costs (online supplemental 9 and 10). Regression analysis revealed a significant 30% reduction in medical costs and a 29.3% reduction in total costs in the hospitalist group compared with the non-hospitalist group ($e^{-0.355}=0.701$, p=0.000; $e^{-0.346}=0.707$, p=0.000; respectively). Furthermore, there was a significant reduction of 28.6% in direct costs and a 23.3% reduction in indirect costs in the hospitalist group compared with the non-hospitalist group $(e^{-0.336}=0.714, p=0.000; e^{-0.265}=0.767, p=0.000;$ respectively).

by clinical variables, KTAS scores, ACCI scores, major diagnoses and age (table 3). Among the total group of patients, the net-benefit and BCR of the AMU hospitalist care group were \$6846 and 1.33 per patient admission, respectively; overall net-benefit of AMU hospitalist care was found to be largely positive. Among the patients stratified by clinical variables, net-benefit and BCR of AMU hospitalist care were found to be largely positive in all but five subgroups (less urgent; ACCI ≥5; diseases of the circulatory system; diseases of the genitourinary system and endocrine, nutritional and metabolic diseases).

Sensitivity analysis

The sensitivity analysis results for LOS and ED-LOS are shown in figure 1A,B. We analysed the 1%-trimmed mean and excluded patients with extreme values, as noted. After excluding extreme values related to LOS, the results were stable (net-benefit: \$7162 to \$8067, BCR: 1.31 to 1.33) and showed no significant difference from the baseline analysis. Sensitivity analysis for ED-LOS revealed that the results were similar to (net-benefit: \$6311 to \$6846, BCR: 1.31 to 1.33) the baseline analysis. After varying paid care costs from \$0 to \$122, the sensitivity analysis results were stable, with the net-benefit ranging from \$8013 to

Renefit-cost analysis

KTAS More urgency (n=5556) 20334 29074 8740 Less urgency (n=835) 21801 14269 -7532 ACCI ACCIS2 (n=1747) 16700 29640 12941 ACCI=3 (n=1169) 24948 34965 10017 ACCI=4 (n=1445) 14346 22545 8199 ACCI≥5 (n=2030) 25890 24894 -996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the digestive system (n=1141) 12369 18568 6199 Diseases of the genitourinary system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039	1.33 1.43 0.65 1.77 1.40 1.57 0.96 1.71 0.51 1.50
More urgency (n=5556) 20 334 29 074 8740 Less urgency (n=835) 21 801 14 269 -7532 ACCI ACCI ≤ (n=1747) 16 700 29 640 12 941 ACCI=3 (n=1169) 24 948 34 965 10 017 ACCI=4 (n=1445) 14 346 22 545 8199 ACCI≥5 (n=2030) 25 890 24 894 -996 Major disease Malignant neoplasms (n=1735) 37 059 63 186 26 127 Diseases of the circulatory system (n=600) 21 568 10 963 -10604 Diseases of the digestive system (n=865) 10 408 19 732 9324 Diseases of the genitourinary system (n=577) 14 018 11 979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10 762 4038	0.65 1.77 1.40 1.57 0.96
Less urgency (n=835) 21801 14269 -7532 ACCI ACCI≤2 (n=1747) 16700 29640 12941 ACCI=3 (n=1169) 24948 34965 10017 ACCI=4 (n=1445) 14346 22545 8199 ACCI≥5 (n=2030) 25890 24894 -996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the genitourinary system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	0.65 1.77 1.40 1.57 0.96
ACCI≤2 (n=1747) 16700 29640 12941 ACCI=3 (n=1169) 24948 34965 10017 ACCI=4 (n=1445) 14346 22545 8199 ACCI≥5 (n=2030) 25890 24894 -996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	1.77 1.40 1.57 0.96
ACCI≤2 (n=1747) 16700 29640 12941 ACCI=3 (n=1169) 24948 34965 10017 ACCI=4 (n=1445) 14346 22545 8199 ACCI≥5 (n=2030) 25890 24894 -996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	1.40 1.57 0.96 1.71 0.51
ACCI=3 (n=1169) 24948 34965 10017 ACCI=4 (n=1445) 14346 22545 8199 ACCI≥5 (n=2030) 25890 24894 -996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	1.40 1.57 0.96 1.71 0.51
ACCI=4 (n=1445) 14346 22545 8199 ACCI≥5 (n=2030) 25890 24894 −996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 −10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 −2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	1.57 0.96 1.71 0.51
ACCI≥5 (n=2030) 25890 24894 -996 Major disease Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	0.96 1.71 0.51
Major disease Malignant neoplasms (n=1735) 37 059 63 186 26 127 Diseases of the circulatory system (n=600) 21 568 10 963 -10604 Diseases of the respiratory system (n=1141) 12 369 18 568 6199 Diseases of the digestive system (n=865) 10 408 19 732 9324 Diseases of the genitourinary system (n=577) 14 018 11 979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10 762 4038	1.71 0.51
Malignant neoplasms (n=1735) 37059 63186 26127 Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	0.51
Diseases of the circulatory system (n=600) 21568 10963 -10604 Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	0.51
Diseases of the respiratory system (n=1141) 12369 18568 6199 Diseases of the digestive system (n=865) 10408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	
Diseases of the digestive system (n=865) 10 408 19732 9324 Diseases of the genitourinary system (n=577) 14018 11979 -2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10 762 4038	1.50
Diseases of the genitourinary system (n=577) 14018 11979 –2039 Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	
Symptoms, signs, and abnormal clinical and laboratory 6724 10762 4038	1.90
	0.85
	1.60
Certain infectious and parasitic diseases (n=290) 5411 22358 16947	4.13
Endocrine, nutritional, and metabolic diseases (n=253) 13906 5765 -8142	0.41
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (n=177)	5.23
Diseases of the musculoskeletal system and connective 9269 19916 10647 tissue (n=147)	2.15
Others (n=277) 19377 28223 8846	1.46
Age (years)	
<50 (n=1098) 34234 46473 12238	1.36
50–59 (n=900) 36276 66967 30691	1.85
60–69 (n=1275) 14345 22699 8354	1.58
70–79 (n=1763) 11861 15868 4007	1.34
≥80 (n=1355) 9310 12453 3143	1.34
Data are presented as mean. Cost unit: USD (US Dollar), (\$1=1307.9 KRW, year: 2023) ACCI, Age-adjusted Charlson Comorbidity Index; HG, hospitalist group; KTAS, Korean Triage and Acuity Scale; NHG, non-hospitalist group.	

\$8138 and the BCR from 1.32 to 1.34 (figure 1C). Oneway sensitivity analysis results showed comparative values of resident, specialist and hospitalist labour costs (online supplemental 11–13), with resident labour costs ranging from \$37350 to \$52,669, which indicated a net-benefit ranging from \$6841 to \$6851 (BCR, 1.33) (online supplemental 11). After varying specialist labour costs from \$76458 to \$152,917, the results were similar to baseline estimates, with net-benefit ranging from \$6764 to \$6924 (BCR, 1.33) (online supplemental 12).

After varying hospitalist labour costs from \$76458 to \$152,917, the results were stable, with the net-benefit ranging from \$6784 to \$6910 (BCR, 1.33) (online supplemental 13).

Two-way sensitivity analysis results on hospitalist and resident labour costs showed that net-benefit ranged from \$6779 to \$6916 and BCR from 1.33 to 1.34 (online supplemental 14). Moreover, two-way sensitivity analysis results on hospitalist and specialist labour costs showed

DISCUSSION Study summary

This study is the first to report on the economic efficiency of a Korean AMU hospitalist care model while controlling for clinical factors. We found a notable cost reduction with AMU hospitalist care compared with non-hospitalist & care in all areas: medical costs, direct costs, indirect costs and total costs. In this study, medical costs included hospitalist care fees. The same trend towards cost reduction was observed in the subgroup and regression analyses. In this study, the cost of doctor labour was estimated separately for each hospitalisation flow and day and night shifts (online supplemental 4).

The net-benefit and BCR analysis results of the AMU hospitalist care group were \$6846 and 1.33 per patient admission, respectively; overall, the net-benefit of AMU hospitalist care was found to be largely positive. Sensitivity analysis showed that the net-benefit and BCR results of AMU hospitalist care were similar to baseline analysis.

In the present resident training system, which lacks a structured curriculum, training has taken the form of encountering more patients and accumulating experience over time. Many institutions still use the apprenticeship model of training to become specialists. The Medical Resident Act has been enacted to address this issue; however, the situation remains ambiguous in the field.³⁷ Moreover, residents who rotate annually or monthly will inevitably experience strained relationships with other professional teams, and medical treatment is frequently interrupted due to complications such as doctor-nurse disputes.² However, direct, real-time communication among our multidisciplinary team members, which enables appropriate and quick decision-making on treatments for patients with acute diseases, is a key component of our AMU care.3

Furthermore, consultation, formulation and implementation of treatment plans and the treatment itself are responsibilities shared among residents, fellows and attending specialists in the context of resident/attending specialist care. However, hospitalists carry the sole responsibility for all these tasks.³⁸ Moreover, hospitalists have extensive knowledge and proficiency in managing patients who are hospitalised. Their level of professionalism is unparalleled compared with that of residents with 1-2 years of experience, as evidenced by their critical thinking skills, patient communication capabilities and accountability for treatment.³⁸ Consequently, these characteristics are believed to help reduce overall costs, including medical costs.

Furthermore, our previous study reported that AMU hospitalist care improved patient outcomes in terms of IHM, ICU admission rate, LOS and ED-LOS.⁹ This enhanced performance may have led to a reduction in indirect expenses and productivity loss.

Direct medical costs

Some previous studies that investigated the costs of hospitalist care have reported reduced medical costs in hospitalist care. 10 39-46 In contrast, other studies have reported no significant difference in total medical costs between patients treated by hospitalists and those treated by non-hospitalists 7 47 and that the costs of care for hospitalists were more than those for specialists but less than those for generalists.⁴⁸ Our study showed that there was a marked cost reduction in consultation, admission, treatment and surgery, medical examination and therapeutic materials fees among the medical cost subcategories. Even when hospitalist care fees were included in medical costs, the hospitalist group's medical costs were lower, which indicates that the difference would be even greater if hospitalist care fees were excluded. Among the previous studies, one study that evaluated Korean hospitalists reported that medical costs reduced by \$208 in

terms of hospitalist care. 10 However, in our study, medical expenses per admission decreased by nearly \$1000 in the hospitalist care group. Both research findings regarding medical cost reduction are comparable, but our study's findings on cost-reduction suggest a more substantial reduction is involved.

The patient group in our study consisted of patients with acute medical conditions admitted through the ED of a tertiary general hospital, with their disease severity being higher than that among those in the total group of patients, which may explain the difference in study results. However, the regression analyses showed a significant 30% reduction in medical costs in the hospitalist group after adjusting for clinical factors. Despite the conflicting results reported in earlier studies, our research findings offer compelling evidence supporting the effectiveness of the AMU hospitalist care model in reducing medical costs.

Direct non-medical costs compared with indirect costs
Studies are lacking on the economic implications of a hospitalist care from a societal perspective. Hence, we conducted an estimation and analysis of non-medical expenses to assess the economic feasibility of AMU hospitalist care from a societal perspective.

In a previous study, we reported that AMU hospitalist care considerably improved patient outcomes in terms of IHM, ICU admission rate, LOS and ED-LOS.⁹ In this study, we used patient outcomes from that study to estimate the following costs: family caregiver transportation fares in hospitalisation, paid care costs in hospitalisation, patient productivity loss based on LOS, family caregiver productivity loss based on LOS, patient productivity loss based on ED-LOS and patient productivity loss based on IHM.

The hospitalist care group's decreased LOS resulted > in a notable reduction in expenses related to family caregiver transportation and paid care during patient hospitalisation.

With the exception of patient productivity loss based on LOS, substantial reductions in expenses were shown for family caregiver productivity loss based on LOS and patient productivity loss based on ED-LOS and IHM. The hospitalist group exhibited a considerably reduced LOS in comparison to the non-hospitalist group. However, it is possible that the lower age of the patients in the hospitalist group may account for & the larger patient productivity loss based on the LOS observed in this group. Nevertheless, AMU hospitalist care resulted in notable reductions in the indirect costs, surpassing \$7000 in savings when compared with the non-hospitalist group. This improvement in patient outcomes played a pivotal role in achieving these cost reductions. Therefore, the overall costs in relation to the AMU hospitalist care group showed a notable decrease in comparison to the non-hospitalist group.

Benefit-cost analysis

The net-benefit and BCR analysis of the AMU hospitalist care group yielded results of \$6846 and 1.33 per patient admission, respectively, indicating that the overall net-benefit of AMU hospitalist care was found to be largely positive. However, variations in net-benefit and BCR analysis ranges were seen across different subgroups (-\$10604 to \$52948, 0.41 to 5.23; respectively). This indicates that the economic efficacy of AMU hospitalist care varies based on the clinical characteristics of patients. Nevertheless, in terms of net-benefit and BCR results, the overall net-benefit of AMU hospitalist care was found to be largely positive in 17 subgroups and negative in five subgroups (less urgent; ACCI ≥5; diseases of the circulatory system; diseases of the genitourinary system; and endocrine, nutritional and metabolic diseases). It is possible that this population has a greater demand for specialised care; furthermore, treatment modalities and expenses can vary substantially based on the reason for admission even for the same disease. In our study, clinical variables were adjusted for factors such as age, severity, the major disease and KTAS. To determine the precise reason for the negative results reported in these five groups, more research into the variables leading to hospitalisation or disease-specific clinical outcomes is required.

These findings might potentially serve as a valuable reference for the development of a more efficient hospitalist care paradigm in further research.

A one-way sensitivity analysis was conducted to examine the impact of variations in the LOS, ED-LOS, paid care costs and doctor labour costs. The netbenefit and BCR analysis results of AMU hospitalist care were stable based on a one-way sensitivity analysis using these four variables. The results of a two-way sensitivity analysis indicated that the net-benefit and BCR results of AMU hospitalist care were similar to the baseline estimates despite fluctuations in labour costs for the resident, specialist and hospitalist.

Limitations

This study had some limitations. First, it employed a retrospective design, which posed challenges in mitigating the effect of confounding factors and discerning whether the observed results were attributable to the AMU environment or the treatment administered by the hospitalists. Second, the study was conducted at a single site, which limits the extent to which our findings may be generalised. Third, other expenditures, excluding medical expenses, were not directly obtained but rather calculated by consulting relevant sources, which introduced a degree of uncertainty into the cost estimations. Fourth, the present study could not provide a quantifiable assessment of the potential benefits associated with the reduction of ICU admissions. Five, the value and benefits of teaching services were not evaluated in this study.

Even if costs are higher for teaching services than for non-teaching services, training future physicians is a valuable goal. Hence, further investigation to ascertain the value and benefits of teaching services from a societal perspective is required.

CONCLUSION

This study showed that AMU hospitalist care significantly reduced costs in nearly all categories, including medical costs, direct costs, indirect costs and total costs. Moreover, in the benefit—cost analysis, the netbenefit and BCR results of the AMU hospitalist care group were shown to be greater than \$6000 and 1.30 per patient admission, respectively. These results indicate that the overall net-benefit of AMU hospitalist care is largely positive. Nevertheless, further investigation is necessary to identify the factors that contribute to hospitalisation or disease-specific clinical outcomes.

Acknowledgements We would like to thank Editage (www.editage.co.kr) for English language editing.

Contributors Conceptualisation: HJK, JK, JHO, N-HK. Methodology: HJK, JK, JHO, N-HK. Software: HJK. Validation: HJK, JK, JHO, N-HK. Formal analysis: HJK. Investigation: HJK, JK, JHO, N-HK. Data curation: HJK. Writing—original draft: HJK. Writing—review and editing: HJK, JK, JHO, N-HK. All authors have read and approved the final draft of the manuscript. JK is the guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Ethical approval was provided by the Institutional Review Board of Seoul National University Bundang Hospital (IRB Number B-1711/435-107). Our institution's ethics committee waived the need for informed consent owing to the retrospective nature of the study and the use of anonymised data previously collected for routine clinical care.

Provenance and peer review Not commissioned; externally peer-reviewed.

Data availability statement Data are available upon reasonable request. Data are available from the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Hyun Jeong Kim http://orcid.org/0000-0003-1993-0593 Jinhyun Kim http://orcid.org/0000-0001-7141-1606 Jung Hun Ohn http://orcid.org/0000-0001-5415-4505 Nak-Hyun Kim http://orcid.org/0000-0003-1134-1364

REFERENCES

- 1 Eom JS. Operating the hospitalist system. *J Korean Med Assoc* 2016:59:342–4
- 2 Shin D-H. The vision of hospitalist system in Korea. Korean J Med 2021:96:1–6.
- 3 Ohn JH, Kim N-H, Kim ES, et al. An acute medical unit in a Korean tertiary care hospital reduces the length of stay and waiting time in the emergency department. J Korean Med Sci 2017;32:1917–20.
- 4 Lee JH, Kim AJ, Kyong TY, et al. Evaluating the outcome of multimorbid patients cared for by Hospitalists: a report of integrated medical model in Korea. J Korean Med Sci 2019;34:e179.
- 5 Jang S-I. Korean hospitalist system implementation and development strategies based on pilot studies. *J Korean Med Assoc* 2019;62:558–63.
- 6 Han SJ, Jung H-W, Oh D-Y, et al. Comparisons of clinical outcomes between weekday-only and full-time, 24-hour/7-day coverage hospitalist systems. J Korean Med Sci 2020;35:e117.
- 7 Jung YB, Jung E-J, Lee KY. A surgical hospitalist system in Korea: a preliminary study of the effects on hospital costs and postoperative outcomes. *Ann Surg Treat Res* 2021;100:298–304.
- 8 Kim ES, Ohn JH, Lim Y, et al. Effect of active surgical comanagement by medical hospitalists in urology inpatient care: a retrospective cohort study. Yonsei Med J 2023;64:558–65.
- 9 Kim HJ, Kim J, Ohn JH, et al. Impact of hospitalist care model on patient outcomes in acute medical unit: a retrospective cohort study. BMJ Open 2023;13:e069561.
- 10 Jang S-I, Yoon JH, Moon SD, et al. A study on the implementation and the evaluation of korean hospitalist system to improve the quality of hospitalization (phase 3). Seoul: Institute of Health Services Research, Yonsei University, 2022.
- 11 Lee TJ, Kim YH, Shin SJ, et al. Costing methods in healthcare. Seoul: National Evidence-based Healthcare Collaborating Agency, 2012.
- Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care 2022;38:e13.
- 13 Kim J, Kwon HY, Hong JH, et al. A Guineline for economic evaluation for Korean medicine. Guideline Center for Korean Med; 2018
- 14 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
- 15 Lee I, Kim O, Kim C, et al. Validity analysis of Korean triage and acuity scale. J Korean Soc Emerg Med 2018;29:13–20.
- 16 Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.
- 17 Yang BM, Kim J, Lee TJ, et al. Health economics (revision). Nanam 2015;363–6.
- 18 National health insurance service. Available: https://www.nhis.or.kr/english/wbheaa02300m 01.do [Accessed 19 Feb 2024].
- 19 Health insurance review & assessment service, Available: https:// www.hira.or.kr/dummy.do?pgmid=HIRAJ010000006000 [Accessed 19 Feb 2024].
- 20 Moon S, Gang T, Oh H, et al. Korea health panel study. NHIS 2017.
- 21 2019 annual report on the consumer price index. Available: https://kosis.kr/publication/publicationThema.do [Accessed 17 Aug 2023].
- 22 Yi JS, Kim J. The social cost of informal nursing care and its policy implications for integrated nursing and care services. Korean J Health Econ Policy 2021;27:97–118.
- 23 2017 resident training environment evaluation survey results, Available: http://www.bosa.co.kr/news/articleView.html?idxno= 2077118 [Accessed 15 Aug 2023].
- 24 Comparison of 4 major SIS's (social insurance schemes). Available: https://www.4insure.or.kr/ins4/ptl/Main.do [Accessed 16 Aug 2023].
- 25 Tax rate. Available: https://www.nts.go.kr/nts/cm/cntnts/cntntsView.do?mi=2227&cntntsId [Accessed 16 Aug 2023].

- 26 2020 resident training environment evaluation survey results. Available: http://www.monews.co.kr/news/articleView.html?idxno= 303414 [Accessed 15 Aug 2023].
- 27 Specialist salary survey result. Available: https://mpak.or.kr/article/% EA%B0%84%E D%96%89%EB%AC%BC/7/60/?page= [Accessed 9 Feb 2024].
- 28 Seoul national University Bundang hospital: inpatient bed. Available: https://www.hira.or.kr/ [Accessed 9 Feb 2024].
- 29 Specialist by clinical field. Available: https://www.snubh.org/medical/deptList.do [Accessed 9 Feb 2024].
- 30 Jang S-I, Park E, Nam J, et al. A study on the implementation and the evaluation of korean hospitalist system to improve the quality of hospitalization (phase 2). Seoul: Institute of Health Services Research, Yonsei University, 2018.
- 31 2017 resident training environment evaluation survey results.
 Available: http://www.Monews.co.kr/news/articleView.html?idxno=
 110624 [Accessed 9 Feb 2024].
- 32 2017 survey report on labor conditions by employment type. Available: https://kosis.kr/publication/publicationThema.do [Accessed 15 Aug 2023].
- 33 2017 annual report on the the economically active population survey. Available: https://kosis.kr/publication/publicationThema.do [Accessed 15 Aug 2023].
- 34 2017 life tables for Korea. Available: https://kosis.kr/publication/publicationThema.do [Accessed 20 Jul 2023].
- 35 Ko JY, Yoon JY. Economic evaluation of hospital-based home care services for the breast cancer surgery patients. J Korean Acad Community Health Nurs 2021;32:356–67.
- 36 Exchange rate. 2023. Available: https://spot.wooribank.com/pot/ Dream?withyou=FXXRT0016 [Accessed 10 Feb 2024].
- 37 Oh SJ, Jung S-M. Development of the role of teaching hospitalists in the education of residents. J Korean Med Assoc 2019;62:573–6.
- 38 Kim HW. The current status of hospital medicine in Korea, 2019. Korean J Med 2019;94:139–44.
- 39 Manzano J-G, Park A, Lin H, et al. Demonstrating value: association of cost and quality outcomes with implementation of a value-driven oncology-hospitalist inpatient collaboration for patients with lung cancer. BMJ Open Qual 2019;8:e000381.
- 40 Hock Lee K, Yang Y, Soong Yang K, et al. Bringing generalists into the hospital: outcomes of a family medicine hospitalist model in Singapore. J Hosp Med 2011;6:115–21.
- 41 Shu C-C, Lin J-W, Lin Y-F, et al. Evaluating the performance of a hospitalist system in Taiwan: a pioneer study for nationwide health insurance in Asia. J Hosp Med 2011;6:378–82.
- 42 Landrigan CP, Srivastava R, Muret-Wagstaff S, et al. Impact of a health maintenance organization hospitalist system in academic pediatrics. *Pediatrics* 2002;110:720–8.
- 43 Auerbach AD, Wachter RM, Katz P, et al. Implementation of a voluntary hospitalist service at a community teaching hospital: improved clinical efficiency and patient outcomes. Ann Intern Med 2002;137:859–65.
- 44 Lundberg S, Balingit P, Wali S, et al. Cost-effectiveness of a hospitalist service in a public teaching hospital. Acad Med 2010;85:1312–5.
- 45 Hrycko A, Tiwari V, Vemula M, et al. A Hospitalist-led team to manage patient boarding in the emergency department: impact on hospital length of stay and cost. South Med J 2019;112:599–603.
- 46 Davis KM, Koch KE, Harvey JK, et al. Effects of hospitalists on cost, outcomes, and patient satisfaction in a rural health system. Am J Med 2000;108:621–6.
- 47 Rachoin J-S, Skaf J, Cerceo E, et al. The impact of hospitalists on length of stay and costs: systematic review and meta-analysis. In: Database of abstracts of reviews of effects (DARE): quality-assessed reviews. Centre for Reviews and Dissemination (UK), 2012. Available: https://www.ncbi.nl m.nih.gov/books/NBK97905/
- 48 Everett G, Uddin N, Rudloff B. Comparison of hospital costs and length of stay for community internists, hospitalists, and academicians. J Gen Intern Med 2007;22:662–7.